Interplay between nuclear transport and ubiquitin/SUMO modifications in the regulation of cancer-related proteins

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 11-19

  Rodríguez, Jose A ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

CRM1; NES; NLS; Nucleocytoplasmic transport; Sumoylation; Ubiquitylation

Indexed keywords

DEUBIQUITINASE; EXPORTIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; SUMO PROTEIN; UBIQUITIN;

CANCER RESEARCH; ENZYME ACTIVITY; HUMAN; MOLECULAR SIZE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; PROTEOMICS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION; ACTIVE TRANSPORT; ANIMAL; GENETICS; METABOLISM; NEOPLASM;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; HUMANS; NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 84904461202     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.03.005     Document Type: Review

References (135)

1. Görlich D., Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999, 15:607-660.
2. Wente S.R., Rout M.P. The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol 2010, 2:a000562.
3. Mingot J.M., Kostka S., Kraft R., Hartmann E., Görlich D. Importin 13: a novel mediator of nuclear import and export. EMBO J 2001, 20:3685-3694.
4. Tran E.J., Bolger T.A., Wente S.R. SnapShot: nuclear transport. Cell 2007, 131:420.
5. Xu D., Farmer A., Chook Y.M. Recognition of nuclear targeting signals by Karyopherin-β proteins. Curr Opin Struct Biol 2010, 20:782-790.
6. Chook Y.M., Süel K.E. Nuclear import by karyopherin-βs: recognition and inhibition. Biochim Biophys Acta 2011, 1813:1593-1606.
7. Fabbro M., Henderson B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003, 282:59-69.
8. Melchior F. Ran GTPase cycle: one mechanism - two functions. Curr Biol 2001, 11:R257-R260.
9. Weis K. Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 2003, 112:441-451.
10. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
11. Ranganathan P., Yu X., Na C., Santhanam R., Shacham S., Kauffman M., et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120:1765-1773.
12. Lapalombella R., Sun Q., Williams K., Tangeman L., Jha S., Zhong Y., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120:4621-4634.
13. Pathria G., Wagner C., Wagner S.N. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 2012, 132:2780-2790.
14. Bettermann K., Benesch M., Weis S., Haybaeck J. Sumoylation in carcinogenesis. Cancer Lett 2012, 316:113-125.
15. Satija Y.K., Bhardwaj A., Das S. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Int J Cancer 2013, 133:2759-2768.
16. Fulda S., Rajalingam K., Dikic I. Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med 2012, 4:545-556.
17. Yang X.J., Chiang C.M. Sumoylation in gene regulation, human disease, and therapeutic action. F1000Prime Rep 2013, 5:45.
18. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
19. Salmena L., Pandolfi P.P. Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation. Nat Rev Cancer 2007, 7:409-413.
20. Shcherbik N., Haines D.S. Ub on the move. J Cell Biochem 2004, 93:11-19.
21. Ptak C., Wozniak R.W. SUMO and nucleocytoplasmic transport. SUMO Regulation of Cellular Processes 2009, 97-116. Springer, Dordrecht. V.G. Wilson (Ed.).
22. Komander D., Rape M. The ubiquitin code. Annu Rev Biochem 2012, 81:203-229.
23. Flotho A., Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 2013, 82:357-385.
24. Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009, 10:319-331.
25. van Wijk S.J., Timmers H.T. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J 2010, 24:981-993.
26. Metzger M.B., Hristova V.A., Weissman A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 2012, 125:531-537.
27. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
28. Kim J.H., Baek S.H. Emerging roles of desumoylating enzymes. Biochim Biophys Acta 2009, 1792:155-162.
29. Wilkinson K.A., Henley J.M. Mechanisms, regulation and consequences of protein Sumoylation. Biochem J 2010, 428:133-145.
30. Gareau J.R., Lima C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010, 11:861-871.
31. Kravtsova-Ivantsiv Y., Ciechanover A. Non-canonical ubiquitin-based signals for proteasomal degradation. J Cell Sci 2012, 125:539-548.
32. Sriramachandran A.M., Dohmen R.J. SUMO-targeted ubiquitin ligases. Biochim Biophys Acta 2014, 1843:75-85.
33. Perry J.J., Tainer J.A., Boddy M.N. A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem Sci 2008, 33:201-208.
34. Praefcke G.J., Hofmann K., Dohmen R.J. SUMO playing tag with ubiquitin. Trends Biochem Sci 2012, 37:23-31.
35. Gao M., Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell 2005, 19:581-593.
36. Rodriguez M.S., Dargemont C., Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 2001, 276:12654-12659.
37. Stade K., Vogel F., Schwienhorst I., Meusser B., Volkwein C., Nentwig B., et al. A lack of SUMO conjugation affects cNLS-dependent nuclear protein import in yeast. J Biol Chem 2002, 277:49554-49561.
38. Nacerddine K., Lehembre F., Bhaumik M., Artus J., Cohen-Tannoudji M., Babinet C., et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005, 9:769-779.
39. Matunis M.J., Coutavas E., Blobel G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 1996, 135:1457-1470.
40. Mahajan R., Delphin C., Guan T., Gerace L., Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88:97-107.
41. Matunis M.J., Wu J., Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J Cell Biol 1998, 140:499-509.
42. Hutten S., Flotho A., Melchior F., Kehlenbach R.H. The Nup358-RanGAP complex is required for efficient importin alpha/beta-dependent nuclear import. Mol Biol Cell 2008, 19:2300-2310.
43. Hamada M., Haeger A., Jeganathan K.B., van Ree J.H., Malureanu L., Wälde S., et al. Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability. J Cell Biol 2011, 194:597-612.
44. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
45. Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H. Sumoylation of Mdm2 by protein inhibitor of activated STAT [PIAS] and RanBP2 enzymes. J Biol Chem 2002, 277:50131-50136.
46. Kirsh O., Seeler J.S., Pichler A., Gast A., Müller S., Miska E., et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J 2002, 21:2682-2691.
47. Tatham M.H., Kim S., Jaffray E., Song J., Chen Y., Hay R.T. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct Mol Biol 2005, 12:67-74.
48. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., et al. Resolution of sister centromeres requires RanBP2-mediated Sumoylation of topoisomerase IIalpha. Cell 2008, 133:103-115.
49. Bernier-Villamor V., Sampson D.A., Matunis M.J., Lima C.D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002, 108:345-356.
50. Knipscheer P., Flotho A., Klug H., Olsen J.V., van Dijk W.J., Fish A., et al. Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell 2008, 31:371-382.
51. Reverter D., Lima C.D. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 2005, 435:687-692.
52. Werner A., Flotho A., Melchior F. The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell 2012, 46:287-298.
53. Rothenbusch U., Sawatzki M., Chang Y., Caesar S., Schlenstedt G. Sumoylation regulates Kap114-mediated nuclear transport. EMBO J 2012, 31:2461-2472.
54. Golebiowski F., Matic I., Tatham M.H., Cole C., Yin Y., Nakamura A., et al. System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2009, 2(72):ra24.
55. Becker J., Barysch S.V., Karaca S., Dittner C., Hsiao H.H., Berriel Diaz M., et al. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat Struct Mol Biol 2013, 20:525-531.
56. Kim W., Bennett E.J., Huttlin E.L., Guo A., Li J., Possemato A., et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011, 44:325-340.
57. Moutty M.C., Sakin V., Melchior F. Importin α/β mediates nuclear import of individual SUMO E1 subunits and of the holo-enzyme. Mol Biol Cell 2011, 22:652-660.
58. Truong K., Lee T.D., Li B., Chen Y. Sumoylation of SAE2 C terminus regulates SAE nuclear localization. J Biol Chem 2012, 287:42611-42619.
59. Makhnevych T., Ptak C., Lusk C.P., Aitchison J.D., Wozniak R.W. The role of karyopherins in the regulated sumoylation of septins. J Cell Biol 2007, 177:39-49.
60. Bailey D., O'Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem 2004, 279:692-703.
61. Kim Y.H., Sung K.S., Lee S.J., Kim Y.O., Choi C.Y., Kim Y. Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1. FEBS Lett 2005, 579:6272-6278.
62. Itahana Y., Yeh E.T., Zhang Y. Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol 2006, 26:4675-4689.
63. Goeres J., Chan P.K., Mukhopadhyay D., Zhang H., Raught B., Matunis M.J. The SUMO-specific isopeptidase SENP2 associates dynamically with nuclear pore complexes through interactions with karyopherins and the Nup 107-160 nucleoporin subcomplex. Mol Biol Cell 2011, 22:4868-4882.
64. Stephen A.G., Trausch-Azar J.S., Ciechanover A., Schwartz A.L. The ubiquitin-activating enzyme E1 is phosphorylated and localized to the nucleus in a cell cycle-dependent manner. J Biol Chem 1996, 271:15608-15614.
65. Stephen A.G., Trausch-Azar J.S., Handley-Gearhart P.M., Ciechanover A., Schwartz A.L. Identification of a region within the ubiquitin-activating enzyme required for nuclear targeting and phosphorylation. J Biol Chem 1997, 272:10895-10903.
66. Plafker S.M., Plafker K.S., Weissman A.M., Macara I.G. Ubiquitin charging of human class III ubiquitin-conjugating enzymes triggers their nuclear import. J Cell Biol 2004, 167:649-659.
67. Groulx I., Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002, 22:5319-5336.
68. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17:554-564.
69. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999, 96:3077-3080.
70. Tajima Y., Goto K., Yoshida M., Shinomiya K., Sekimoto T., Yoneda Y., et al. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor- beta signaling by Smad7. J Biol Chem 2003, 278:10716-10721.
71. Rodríguez J.A., Henderson B.R. Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 2000, 275:38589-38596.
72. Chen C.F., Li S., Chen Y., Chen P.L., Sharp Z.D., Lee W.H. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 1996, 271:32863-32868.
73. Urbé S., Liu H., Hayes S.D., Heride C., Rigden D.J., Clague M.J. Systematic survey of deubiquitinase localization identifies USP21 as a regulator of centrosome- and microtubule-associated functions. Mol Biol Cell 2012, 23:1095-1103.
74. García-Santisteban I., Bañuelos S., Rodríguez J.A. A global survey of CRM1-dependent nuclear export sequences in the human deubiquitinase family. Biochem J 2012, 441:209-217.
75. Soboleva T.A., Jans D.A., Johnson-Saliba M., Baker R.T. Nuclear-cytoplasmic shuttling of the oncogenic mouse UNP/USP4 deubiquitylating enzyme. J Biol Chem 2005, 280:745-752.
76. Gao D., Inuzuka H., Tseng A., Chin R.Y., Toker A., Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol 2009, 11:397-408.
77. Zhang L., Zhou F., Drabsch Y., Gao R., Snaar-Jagalska B.E., Mickanin C., et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol 2012, 14:717-726.
78. Nelson D.E., Laman H. A competitive binding mechanism between Skp1 and exportin 1 (CRM1) controls the localization of a subset of F-box proteins. J Biol Chem 2011, 286:19804-19815.
79. Rodriguez J.A., Schüchner S., Au W.W., Fabbro M., Henderson B.R. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. Oncogene 2004, 23:1809-1820.
80. Li S., Ku C.Y., Farmer A.A., Cong Y.S., Chen C.F., Lee W.H. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 1998, 273:6183-6189.
81. Garcia-Santisteban I., Zorroza K., Rodriguez J.A. Two nuclear localization signals in USP1 mediate nuclear import of the USP1/UAF1 complex. PLoS ONE 2012, 7(6):e38570.
82. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
83. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990, 10:6565-6577.
84. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18:1660-1672.
85. Zhang Y., Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001, 292:1910-1915.
86. Kawaguchi Y., Ito A., Appella E., Yao T.P. Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. J Biol Chem 2006, 281:1394-1400.
87. Kanai M., Hanashiro K., Kim S.H., Hanai S., Boulares A.H., Miwa M., et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2007, 9:1175-1183.
88. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003, 13:49-58.
89. Nakamura S., Roth J.A., Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000, 20:9391-9398.
90. Rodriguez M.S., Desterro J.M., Lain S., Lane D.P., Hay R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000, 20:8458-8467.
91. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302:1972-1975.
92. Lohrum M.A., Woods D.B., Ludwig R.L., Bálint E., Vousden K.H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001, 21:8521-8532.
93. Gu J., Nie L., Wiederschain D., Yuan Z.M. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol Cell Biol 2001, 21:8533-8546.
94. Carter S., Bischof O., Dejean A., Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 2007, 9:428-435.
95. Santiago A., Li D., Zhao L.Y., Godsey A., Liao D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell 2013, 24:2739-2752.
96. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindström M.S., et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007, 12:355-366.
97. Hock A.K., Vousden K.H. The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta 2014, 1843:137-149.
98. Nikolaev A.Y., Li M., Puskas N., Qin J., Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003, 112:29-40.
99. Laine A., Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007, 26:1477-1483.
100. Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 2007, 26:113-122.
101. Kruse J.P., Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 2009, 284:3250-3263.
102. Brooks C.L., Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006, 21:307-315.
103. Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010, 140:384-396.
104. Quin J.E., Devlin J.R., Cameron D., Hannan K.M., Pearson R.B., Hannan R.D. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta 2014, [Epub ahead of print].
105. Boyd M.T., Vlatkovic N., Rubbi C.P. The nucleolus directly regulates p53 export and degradation. J Cell Biol 2011, 194:689-703.
106. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
107. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010, 42:454-458.
108. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245.
109. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of PTEN. J Cell Sci 2008, 121:249-253.
110. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
111. Gil A., Andrés-Pons A., Fernández E., Valiente M., Torres J., Cervera J., et al. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 2006, 17:4002-4013.
112. Bassi C., Ho J., Srikumar T., Dowling R.J., Gorrini C., Miller S.J., et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-399.
113. Li A.G., Piluso L.G., Cai X., Wei G., Sellers W.R., Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 2006, 23:575-587.
114. Chang C.J., Mulholland D.J., Valamehr B., Mosessian S., Sellers W.R., Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 2008, 28:3281-3289.
115. Song M.S., Carracedo A., Salmena L., Song S.J., Egia A., Malumbres M., et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011, 144:187-199.
116. Liu F., Wagner S., Campbell R.B., Nickerson J.A., Schiffer C.A., Ross A.H. PTEN enters the nucleus by diffusion. J Cell Biochem 2005, 96:221-234.
117. Chung J.H., Ginn-Pease M.E., Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005, 65:4108-4116.
118. Denning G., Jean-Joseph B., Prince C., Durden D.L., Vogt P.K. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 2007, 26:3930-3940.
119. Trotman L.C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
120. Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128:129-139.
121. Howitt J., Lackovic J., Low L.H., Naguib A., Macintyre A., Goh C.P., et al. Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J Cell Biol 2012, 196:29-36.
122. Hamilton M.H., Tcherepanova I., Huibregtse J.M., McDonnell D.P. Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates. J Biol Chem 2001, 276:26324-26331.
123. Van Themsche C., Leblanc V., Parent S., Asselin E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J Biol Chem 2009, 284:20462-20466.
124. Maddika S., Kavela S., Rani N., Palicharla V.R., Pokorny J.L., Sarkaria J.N., et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 2011, 13:728-733.
125. Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., Teruya-Feldstein J., et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008, 455:813-817.
126. Zhang J., Zhang P., Wei Y., Piao H.L., Wang W., Maddika S., et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol 2013, 15:1486-1494.
127. Yim E.K., Peng G., Dai H., Hu R., Li K., Lu Y., et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
128. Noguera N.I., Song M.S., Divona M., Catalano G., Calvo K.L., García F., et al. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 2013, 27:1037-1043.
129. Morotti A., Panuzzo C., Crivellaro S., Pergolizzi B., Familiari U., Berger A.H., et al. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia 2013, [Epub ahead of print].
130. Huang J., Yan J., Zhang J., Zhu S., Wang Y., Shi T., et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 2012, 3:911.
131. Cai Q., Robertson E.S. Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS ONE 2010, 5(9). pii: e12636.
132. van der Horst A., de Vries-Smits A.M., Brenkman A.B., van Triest M.H., van den Broek N., Colland F., et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006, 8:1064-1073.
133. Tauriello D.V., Maurice M.M. The various roles of ubiquitin in Wnt pathway regulation. Cell Cycle 2010, 9:3700-3709.
134. Al-Salihi M.A., Herhaus L., Sapkota G.P. Regulation of the transforming growth factor β pathway by reversible ubiquitylation. Open Biol 2012, 2(5):120082.
135. Mattern M.R., Wu J., Nicholson B. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta 2012, 1823:2014-2021.